Baseline clinical characteristics of the 34 PiZ subjects studied over 3 years
| Median (IQR) | Median % predicted | |
|---|---|---|
| *All lung function measurements were performed after dual bronchodilation with inhaled nebulised salbutamol (2.5 mg) and ipratropium bromide (250 μg). | ||
| FEV1, forced expiratory volume in 1 second; VC, vital capacity; RV, residual volume; TLC, total lung capacity (helium dilution); Kco, lung carbon monoxide transfer factor (mmol/min/kPa/l); UZ, upper zone scans; LZ, lower zone scans; Combined, average of upper and lower zone scans; Perc15, 15th percentile point; VI −950, voxel index at a threshold of −950 HU. | ||
| Age | 51 (47–56) | N/A |
| Pack years | 16 (0–26) | N/A |
| FEV1 (l)* | 1.2 (0.9–1.9) | 42 |
| VC (l)* | 3.9 (3.9–4.7) | 100 |
| RV (l)* | 2.7 (2.2–3.4) | 126 |
| TLC (l)* | 6.9 (6.2–8.3) | 117 |
| Kco* | 1.0 (0.8–1.3) | 68 |
| UZ Perc15 | −942.3 (−964.9 to −926.9) | N/A |
| UZ VI −950 | 11.8 (6.2–23.9) | N/A |
| LZ Perc15 | −969.9 (−977.6 to −943.1) | N/A |
| LZ VI −950 | 28.3 (11.5–34.1) | N/A |